Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or ...

A new daily pill could offer a major breakthrough for people living with type 2 diabetes and struggling with weight management ...

Zydus plans to launch its diabetes and obesity injection using a reusable adjustable pen device after patent expiry, as more Indian drugmakers enter the market.

India’s market for anti-obesity medicines is expected to undergo a significant shift in 2026, with prices of leading weight-loss injections likely to fall sharply. Industry estimates indicate that ...

Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabs ...

This summer, Norton Healthcare hopes to launch a new islet cell program to help treat chronic pancreatitis and eventually Type 1 diabetes patients.

Here’s something big: scientists in China have actually reversed type 2 diabetes using stem-cell therapy. It’s a major step ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.

The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a ...

Ahmedabad: Zydus Lifesciences Limited said it plans to launch semaglutide injection in India under the brand names Semaglyn, Mashema and Alterme after.